{"count": 2, "results": [{"_id": "33967957", "pmid": 33967957, "pmcid": "PMC8104028", "title": "Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases", "journal": "Front Endocrinol (Lausanne)", "authors": ["Lin CY", "Wu CH", "Hsu CY", "Chen TH", "Lin MS", "Lin YS", "Su YJ"], "date": "2021-04-23T00:00:00Z", "doi": "10.3389/fendo.2021.641635", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "641635", "score": 50280.01, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ may add benefits beyond @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@ control with regard to reducing all-cause mortality and admission rate, as well as minimizing @<m>DISEASE_Insulin_Like_Growth_Factor_I_Resistance_To</m> @DISEASE_MESH:C564816 @@@end-organ injury@@@ in @DISEASE_Lung_Diseases @DISEASE_MESH:D008171 @@@lungs@@@ and kidneys among @SPECIES_9606 @@@patients@@@ with @DISEASE_Autoimmune_Diseases @DISEASE_MESH:D001327 @@@autoimmune diseases@@@.", "citations": {"NLM": "Lin CY, Wu CH, Hsu CY, Chen TH, Lin MS, Lin YS, Su YJ. Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases Front Endocrinol (Lausanne). 2021;12():641635. PMID: 33967957", "BibTeX": "@article{33967957, title={Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases}, author={Lin CY and Wu CH and Hsu CY and Chen TH and Lin MS and Lin YS and Su YJ}, journal={Front Endocrinol (Lausanne)}, volume={12}, pages={641635}}"}}, {"_id": "31653514", "pmid": 31653514, "title": "Chronic metformin reduces systemic and local inflammatory proteins and improves hypertension-related cardiac autonomic dysfunction.", "journal": "Nutr Metab Cardiovasc Dis", "authors": ["Oliveira PWC", "de Sousa GJ", "Birocale AM", "Gouvêa SA", "de Figueiredo SG", "de Abreu GR", "Bissoli NS"], "date": "2020-02-10T00:00:00Z", "doi": "10.1016/j.numecd.2019.09.005", "meta_date_publication": "2020 Feb 10", "meta_volume": "30", "meta_issue": "2", "meta_pages": "274-281", "score": 50246.125, "text_hl": "CONCLUSION: Chronic @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ presented anti-@DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ and antioxidant effects and, independently of alterations in glycaemia, it improved cardiac autonomic parameters that are impaired in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, being related to @<m>DISEASE_Insulin_Like_Growth_Factor_I_Resistance_To</m> @DISEASE_MESH:C564816 @@@end-organ damage@@@ and mortality. ", "citations": {"NLM": "Oliveira PWC, de Sousa GJ, Birocale AM, Gouvêa SA, de Figueiredo SG, de Abreu GR, Bissoli NS. Chronic metformin reduces systemic and local inflammatory proteins and improves hypertension-related cardiac autonomic dysfunction. Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):274-281. PMID: 31653514", "BibTeX": "@article{31653514, title={Chronic metformin reduces systemic and local inflammatory proteins and improves hypertension-related cardiac autonomic dysfunction.}, author={Oliveira PWC and de Sousa GJ and Birocale AM and Gouvêa SA and de Figueiredo SG and de Abreu GR and Bissoli NS}, journal={Nutr Metab Cardiovasc Dis}, volume={30}, number={2}, pages={274-281}}"}}]}